Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 3/20 | 0.43 |
| ▸ | GUSB | P08236 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584567 | 0.88 | EDNRA (0.41) | EDNRAGUSBMEN1MAPTKMT2A | |
| SCHEMBL8445476 | 0.82 | GUSB (0.37) | EDNRAGUSBMEN1KMT2ANR4A2 | |
| SCHEMBL7676135 | 0.79 | EDNRA (0.46) | EDNRA | |
| SCHEMBL6584222 | 0.79 | EDNRA (0.39) | EDNRAGUSBMEN1MAPTKMT2A | |
| SCHEMBL6586639 | 0.72 | EDNRA (0.40) | EDNRAGUSBMEN1MAPTKMT2A | |
| SCHEMBL6584667 | 0.70 | TAS1R3 (0.39) | EDNRAMEN1MAPTKMT2ARAB9A | |
| SCHEMBL10272715 | 0.69 | NR4A2 (0.44) | GUSBNR4A2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6584800 | 0.69 | TAS1R3 (0.40) | EDNRAMEN1MAPTKMT2ARAB9A | |
| SCHEMBL8444123 | 0.68 | GUSB (0.36) | GUSBMEN1MAPTKMT2ANR4A2 | |
| SCHEMBL6584112 | 0.67 | EDNRA (0.43) | EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901470-B1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6384070-B2 | RESTENOSIS, KIDNEY DISEASES, LUNG DISEASES | PFIZER INC. | 2002-05-07 | — | — | US | disclosed |
| US-6306852-B1 | INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF A VARIETY OF DISEASES INCLUDING RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION, AND TO PHARMACEUTICAL FORMULATIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | RAWSON DAVID JAMES (GB) | 2001-08-16 | — | — | US | disclosed |
| US-6136843-A | CARDIOVASCULAR DISORDERS; KIDNEY DISORDERS | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| US-6017945-A | USEFUL IN THE TREATMENT OF RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION | PFIZER INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0901470-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043260-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | NR1H2, NR1H3, NR1H4 | EDNRA 102/4885GUSB 3576/4885MEN1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.